European Radiology

, Volume 26, Issue 6, pp 1606–1612 | Cite as

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference

  • H. A. Vargas
  • A. M. Hötker
  • D. A. Goldman
  • C. S. Moskowitz
  • T. Gondo
  • K. Matsumoto
  • B. Ehdaie
  • S. Woo
  • S. W. Fine
  • V. E. Reuter
  • E. Sala
  • H. Hricak
Urogenital

Abstract

Objectives

To evaluate the recommendations for multiparametric prostate MRI (mp-MRI) interpretation introduced in the recently updated Prostate Imaging Reporting and Data System version 2 (PI-RADSv2), and investigate the impact of pathologic tumour volume on prostate cancer (PCa) detectability on mpMRI.

Methods

This was an institutional review board (IRB)-approved, retrospective study of 150 PCa patients who underwent mp-MRI before prostatectomy; 169 tumours ≥0.5-mL (any Gleason Score [GS]) and 37 tumours <0.5-mL (GS ≥4+3) identified on whole-mount pathology maps were located on mp-MRI consisting of T2-weighted imaging (T2WI), diffusion-weighted (DW)-MRI, and dynamic contrast-enhanced (DCE)-MRI. Corresponding PI-RADSv2 scores were assigned on each sequence and combined as recommended by PI-RADSv2. We calculated the proportion of PCa foci on whole-mount pathology correctly identified with PI-RADSv2 (dichotomized scores 1–3 vs. 4–5), stratified by pathologic tumour volume.

Results

PI-RADSv2 allowed correct identification of 118/125 (94 %; 95 %CI: 90–99 %) peripheral zone (PZ) and 42/44 (95 %; 95 %CI: 89–100 %) transition zone (TZ) tumours ≥0.5 mL, but only 7/27 (26 %; 95 %CI: 10–42 %) PZ and 2/10 (20 %; 95 %CI: 0–52 %) TZ tumours with a GS ≥4+3, but <0.5 mL. DCE-MRI aided detection of 4/125 PZ tumours ≥0.5 mL and 0/27 PZ tumours <0.5 mL.

Conclusions

PI-RADSv2 correctly identified 94–95 % of PCa foci ≥0.5 mL, but was limited for the assessment of GS ≥4+3 tumours ≤0.5 mL. DCE-MRI offered limited added value to T2WI+DW-MRI.

Key points

• PI-RADSv2 correctly identified 95 % of PCa foci ≥0.5 mL

• PI-RADSv2 was limited for the assessment of GS ≥4+3 tumours ≤0.5 mL

• DCE-MRI offered limited added value to T2WI+DW-MRI

Keywords

Prostate cancer MRI Diffusion DCE PI-RADS 

Abbreviations

DCE-MRI

Dynamic contrast-enhanced MRI

DW-MRI

Diffusion-weighted MRI

GS

Gleason Score

mp-MRI

Multiparametric prostate MRI

MRI

Magnetic resonance imaging

PCa

Prostate cancer

PI-RADS

Prostate Imaging Reporting and Data System

PZ

Peripheral zone

T2WI

T2-weighted images

TZ

Transition zone

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA: Cancer J Clin 64(1):9–29CrossRefGoogle Scholar
  2. 2.
    Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6):1046–1055CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ploussard G, Epstein JI, Montironi R et al (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303CrossRefPubMedGoogle Scholar
  4. 4.
    Polascik TJ, Passoni NM, Villers A, Choyke PL (2014) Modernizing the diagnostic and decision-making pathway for prostate cancer. Clin Cancer Res 20(24):6254–6257CrossRefPubMedGoogle Scholar
  5. 5.
    Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22(4):746–757CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    American College of Radiology. MR Prostate Imaging Reporting and Data System version 2.0. Accessed April 2015, from http://www.acr.org/Quality-Safety/Resources/PIRADS/).
  7. 7.
    Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, et al. (2015) Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol.Google Scholar
  8. 8.
    Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM (2015) Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol 67(6):1112–1121CrossRefPubMedGoogle Scholar
  9. 9.
    Vache T, Bratan F, Mege-Lechevallier F, Roche S, Rabilloud M, Rouviere O (2014) Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiology 272(2):446–455CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenkrantz AB, Kim S, Lim RP et al (2013) Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales. Radiology 269(2):482–492CrossRefPubMedGoogle Scholar
  11. 11.
    Vargas HA, Akin O, Shukla-Dave A, Zhang J, Zheng J, Kanao K, Goldman D, Moskowitz CS, Reuter V, Eastham J, Scardino P, Hricak H (2012) Performance Characteristics of MRI in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. Radiology 265(2):478–487CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© European Society of Radiology 2015

Authors and Affiliations

  • H. A. Vargas
    • 1
  • A. M. Hötker
    • 1
  • D. A. Goldman
    • 2
  • C. S. Moskowitz
    • 2
  • T. Gondo
    • 3
  • K. Matsumoto
    • 3
  • B. Ehdaie
    • 3
  • S. Woo
    • 1
  • S. W. Fine
    • 4
  • V. E. Reuter
    • 4
  • E. Sala
    • 1
  • H. Hricak
    • 1
  1. 1.Department of RadiologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Epidemiology and BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations